US Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment (MS A-110), 26 W. Martin Luther King Dr., Cincinnati, OH, 45268, USA.

This email address is being protected from spam bots, you need Javascript enabled to view it

Individuals diagnosed with specific diseases may represent subpopulations with heightened sensitivity to environmental compounds. This may be due to their disease-mediated molecular milieu and/or the interference of environmental compounds with pharmaceutical drug targets. Prostate cancer represents a significant clinical challenge in the United States. If the disease becomes advanced, standard therapies are ineffective, leading to high rate of patient morbidity and mortality. Understanding the complex reasons for therapeutic resistance is critical for improving the life expectancy for patients with this cancer. Recently, it has been identified that common somatically derived genetic mutations that arise following the selective pressure of standard prostate cancer treatments may facilitate sensitivity to environmental contaminants. These somatic mutations within the androgen receptor allow the estrogen mimic, bisphenol A (BPA), to bind and activate the receptor, resulting in increased proliferation and tumor growth in the presence of the traditional therapy regimen for prostate cancer. In an in vivo xenograft model of prostate cancer, low level exposure of BPA was sufficient to reduce the efficacy of treatment. Herein, the possible effect of BPA on prostate cancer treatment and disease management for humans is explored as an example of environmental endocrine disruptor exposure reducing the efficacy of disease management. These data lend support to the hypothesis that environmental exposure to select compounds may interfere with specific therapeutic regimens.

Written by:
Hess-Wilson JK.   Are you the author?

Reference:
Cancer Causes Control. 2009 Apr 17. Epub ahead of print.
doi: 10.1007/s10552-009-9337-8

PubMed Abstract
PMID:19370395

UroToday.com Prostate Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!